Bristol-Myers Squibb Company (NYSE:BMY) is now up 33.25% compared to a 12-month low of $46.01. We have seen the price to move 0.05% higher and get settled at $61.31 on 01/02/2018. At recent session, it appeared stuck in a range of $60.84 to $61.51. This company shares are 4.16% off its target price of $63.86 and the current market capitalization stands at $101.15B. The recent change has given its price a -1.17% deficit over SMA 50 and -7.25% deficit over its 52-week high. The stock witnessed -2.98% declines, -5.03% declines and 8.96% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BMY’s volatility during a week at 1.13% and during a month it has been found around 1.63%.Bristol-Myers Squibb Company (BMY) Top Holders
Institutional investors currently hold around $70.27 billion or 71.3% in BMY stock. Look at its top three institutional owners. Wellington Management Group Llp owns $9.05 billion in Bristol-Myers Squibb Company, which represents roughly 8.94% of the company’s market cap and approximately 12.87% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 121,788,969 shares of the stock are valued at $7.46 billion. The third largest holder is Blackrock Inc., which currently holds $6.09 billion worth of this stock and that ownership represents nearly 6.02% of its market capitalization.
At the end of 09/30/2017 reporting period, 726 institutional holders increased their position in Bristol-Myers Squibb Company (NYSE:BMY) by some 59,252,443 shares, 721 decreased positions by 61,740,384 and 251 held positions by 1,025,758,292. That puts total institutional holdings at 1,146,751,119 shares, according to SEC filings. The stock grabbed 126 new institutional investments totaling 14,980,822 shares while 69 institutional investors sold out their entire positions totaling 4,101,349 shares.Bristol-Myers Squibb Company (NYSE:BMY) Insider Trades
Multiple company employees have indulged in significant insider trading. Bristol-Myers Squibb Company disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Samuels Theodore R. Ii has acquired 4,000 shares of Bristol-Myers Squibb Company (BMY) in trading session dated Dec. 15, 2017. These shares are worth $249,200 and were traded at $62.3 each. The SEC filing shows that Lynch Thomas J. Jr. performed a sale of 5,300 shares. The EVP & Chief Scientific Officer disposed these shares by way of transaction on Dec. 12, 2017. The company’s shares were given away at $63.24 per share worth to an income of some $335,172 on account of Lynch Thomas J. Jr..
EVP, General Counsel, Leung Sandra, sold 156,582 common shares of Bristol-Myers Squibb Company (BMY) in the open market. In a transaction dated Dec. 04, 2017, the shares were put up for sale at an average price of $63.37, raking in a sum of $9,922,601. After this sale, 433,765 common shares of BMY are directly owned by the insider, with total stake valued at $26,594,132.
In the transaction dated Sep. 06, 2017, the great number of shares disposed came courtesy the SVP & Controller; Caldarella Joseph C disposed a total of 9,340 shares at an average price of $60, amounting to approximately $560,400. The insider now directly owns 48,076 shares worth $2,947,540.
Several analysts have released their opinion on Bristol-Myers Squibb Company (NYSE:BMY), with 7 analysts believing it is a strong buy. Whereas 8 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.25 average brokerage recommendation.